Grifols

Grifols Capital Expenditures

The Capital Expenditures (CapEx) of Grifols (GRF.MC) as of Nov 18, 2026 is -423.00 M EUR. In the previous year, Capital Expenditures (CapEx) was -232.54 M EUR — a change of 81.91% (lower).

Capital Expenditures

-423.00 MEUR

YoY

81.91%

Last updated:

Capital Expenditures (CapEx) of Grifols is 2025 -423.00 M EUR. Capital Expenditures (CapEx) of Grifols was 2024 -232.54 M EUR. It decreases by 81.91% lower compared to the previous year.

The Grifols Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-307.72 M EUR
Jan 1, 2019
-412.31 M EUR
Jan 1, 2020
-362.56 M EUR
Jan 1, 2021
-315.09 M EUR
Jan 1, 2022
-375.56 M EUR
Jan 1, 2023
-295.42 M EUR
Jan 1, 2024
-232.54 M EUR
Jan 1, 2025
-423.00 M EUR
The Grifols Capital Expenditures history
YEARCapital ExpendituresYoY
-423.00 MEUR+81.91%
-232.54 MEUR-21.29%
-295.42 MEUR-21.34%
-375.56 MEUR+19.19%
-315.09 MEUR-13.09%
-362.56 MEUR-12.07%
-412.31 MEUR+33.99%
-307.72 MEUR-4.72%
-322.97 MEUR+10.35%
-292.69 MEUR-48.38%
-567.02 MEUR+97.54%
-287.04 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Grifols Stock analysis

What does Grifols do? Grifols SA is a globally operating company specialized in the manufacture and marketing of medical products and technologies. The company is headquartered in Barcelona, Spain and has been in existence for over 75 years. Grifols focuses on improving the quality of life through the production and marketing of blood products and services, diagnostics, and hospital pharmaceuticals. It has four main business areas: Bioscience, Hospital, Diagnostic, and Bio Supplies. Grifols emphasizes research and development to meet customer needs. It has introduced various products, including AlfaBIO, Vistogard, ID Core XT, NEO Blood Bank, and MIRASOL Pathogen Reduction Technology. Grifols is committed to innovation and quality, providing products and services that cater to a wide range of customers. Additionally, it is a significant employer in the biotechnology industry and contributes to economic development in different regions. Grifols is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grifols stock

Capital Expenditures (CapEx) of Grifols is -423.00 M EUR in 2025.

Capital Expenditures (CapEx) of Grifols changed from -232.54 M EUR to -423.00 M EUR, representing a 81.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Grifols since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Grifols historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Grifols

All Key Metrics — Grifols